leisure time -WSS

leisure time

author：explore 2025-09-06 04:17:34 - browse：41

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Intellia plays down concerns on accidental germline transmission

WSS

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Health officials lay out plans to cope with respiratory virus season

Can U.S. cancer drug shortages be fixed?

Merck, Johnson & Johnson CEOs will testify on high drug prices

Why you shouldn’t ask, “What country has the best health care?”

DeSantis wants to import drugs. Biden’s FDA blasted his plan

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Hollywood unions extend contract negotiations for actors

Abortion policy in the spotlight at Republican debate

Anesthesiologist group: stop taking Ozempic before surgery

National associations that represent hospice owe an apology

How to save PrEP access — and even expand it

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Peter Hotez and the public health issue of online harassment

Bernie Sanders is gearing up to subpoena pharma CEOs

entertainment

Investment in vaccine development is lagging, report finds

Republicans love RFK Jr. What's that tell us about health in 2024?

Health officials lay out plans to cope with respiratory virus season

National associations that represent hospice owe an apology

Why Medicare shouldn’t cover every FDA

Wegovy leads to weight loss. Can it treat depression, too?

leisure time

leisure time

leisure time

explore